Track topics on Twitter Track topics that are important to you
DermaGen AB is a specialty pharmaceutical company and world leader in the research and development of endogenous antimicrobial peptides. Founded in 2004, DermaGen focuses on the development of topically applied products for the prevention and treatment of bacterial and fungal skin infections. Novel antimicrobial peptides are modified to increase their potency and stability, facilitating the development of pharmaceutical products that fulfill unmet medical needs and significantly improve quality of life for patients. DermaGen partners with leading international pharmaceutical companies in the dermatological field to ensure rapid and cost-efficient development. The company is based in Lund, Sweden and is part of the Pergamum group of companies.
It is estimated that 300 million people worldwide will have diabetes by the year 2025. About 12 percent of those with diabetes will have had a foot ulcer, which is a major source of morbid...
DermaGen AB is a specialty pharmaceutical company and world leader in the research and development of endogenous antimicrobial peptides. Founded in 2004, DermaGen focuses on the development of top...
Tishcon's areas of expertise:1. Sustained Release Supplements (tablets, caplets, capsules, softgels) 2. Dual Release Supplements (tablets, caplets) 3. USP Compliant Supplements 4. Bio-SolvTM - Hig...
We have published hundreds of DermaGen AB news stories on BioPortfolio along with dozens of DermaGen AB Clinical Trials and PubMed Articles about DermaGen AB for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of DermaGen AB Companies in our database. You can also find out about relevant DermaGen AB Drugs and Medications on this site too.
Anything that breaks the skin is a wound because when the skin is broken, there's a risk of germs getting into the body and causing an infection. Follow and track Wound Care News on BioPortfolio: Wound Car...